(Credit: Getty Images)

asthma

Could blowing on a bracelet predict asthma attacks?

Scientists have created a sensor that monitors lung inflammation in patients with asthma and other respiratory conditions. The sensor could potentially be used to predict asthma attacks and make diagnosing the condition simpler and more accurate.

The sensor paves the way for the development of devices—possibly resembling fitness trackers like the Fitbit—which people could wear and then know when and at what dosage to take their medication.

“Our vision is to develop a device that someone with asthma or another respiratory disease can wear around their neck or on their wrist and blow into it periodically to predict the onset of an asthma attack or other problems,” says Mehdi Javanmard, an assistant professor in the department of electrical and computer engineering at Rutgers University. “It advances the field of personalized and precision medicine.”

graphene-based asthma device graph
Exhaled breath condensate (tiny droplets of liquid) are rapidly analyzed by a graphene-based nanoelectronic sensor that detects nitrite, a key inflammatory marker in the inner lining of the respiratory airway. (Credit: Azam Gholizadeh/Rutgers)

Javanmard and his fellow team members describe their invention in the journal Microsystems & Nanoengineering.

Asthma, which causes inflammation of the airway and obstructs air flow, affects about 300 million people worldwide. About 17.7 million adults and 6.3 million children in the United States were diagnosed with asthma in 2014. Symptoms include coughing, wheezing, shortness of breath, and chest tightness. Other serious lung ailments include chronic obstructive pulmonary disease (COPD), which encompasses emphysema and chronic bronchitis.

Today’s non-invasive methods for diagnosing and monitoring asthma are limited in characterizing the nature and degree of airway inflammation, and require costly, bulky equipment that patients cannot easily keep with them. The methods include spirometry, which measures breathing capacity, and testing for exhaled nitric oxide, an indicator of airway inflammation. There’s an urgent need for improved, minimally invasive methods for the molecular diagnosis and monitoring of asthma, the study says.

Measuring biomarkers in exhaled breath condensate—tiny liquid droplets discharged during breathing—can contribute to understanding asthma at the molecular level and lead to targeted treatment and better disease management.

The researchers’ miniaturized electrochemical sensor accurately measures nitrite in exhaled breath condensate using reduced graphene oxide. Reduced graphene oxide resists corrosion, has superior electrical properties and is very accurate in detecting biomarkers. Graphene is a thin layer of the graphite used in pencils.

This biomarker can sort out asthma from allergies

“Nitrite level in breath condensate is a promising biomarker for inflammation in the respiratory tract. Having a rapid, easy method to measure it can help an asthmatic determine if air pollutants are affecting them so they can better manage use of medication and physical activity,” says Clifford Weisel, study coauthor and professor at the university’s Environmental and Occupational Health Sciences Institute (EOHSI).

“It could also be used in a physician’s office and emergency departments to monitor the effectiveness of various anti-inflammatory drugs to optimize treatment.”

“Increases in airway inflammation may be an early warning sign of increased risk of an asthma attack or exacerbation of COPD, allowing for earlier and more-effective preventive measures or treatment,” says Robert Laumbach, study coauthor and an occupational and environmental medicine physician at EOHSI.

“Just looking at coughing, wheezing, and other outward symptoms, diagnosis accuracy is often poor, so that’s why this idea of monitoring biomarkers continuously can result in a paradigm shift,” says Javanmard, who works in the School of Engineering. “The ability to perform label-free quantification of nitrite content in exhaled breath condensate in a single step without any sample pre-treatment resolves a key bottleneck to enabling portable asthma management.”

The next step is to develop a portable, wearable system, which could be commercially available within five years, he says. The researchers also envision expanding the number of inflammation biomarkers a device could detect and measure.

Cancer drug may treat severe asthma

“In the US alone, allergy inflammation, asthma, and various respiratory conditions are all on the rise, so devices that can help diagnose, monitor, and manage these conditions will be in high demand,” Javanmard says.

Source: Rutgers University

Related Articles